指南与共识乳腺癌支持与姑息治疗

乳腺癌辅助双膦酸盐及其他骨改良药物应用:ASCO-OH(CCO)指南更新

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
指南 / 共识 · J Clin Oncol · 2022-01-18

美国临床肿瘤学会(ASCO)与安大略健康(CCO)专家小组系统检索新证据后更新乳腺癌辅助骨改良药物指南,推荐应与所有绝经后(自然或治疗所致)原发性乳腺癌且适合接受辅助全身治疗的患者讨论辅助双膦酸盐治疗,不论激素受体和人表皮生长因子受体2状态。

要点

  • 应与所有绝经后(自然或治疗所致)原发性乳腺癌且适合辅助全身治疗的患者讨论辅助双膦酸盐治疗。
  • 辅助双膦酸盐不能替代标准抗肿瘤治疗,其获益取决于复发风险,并与总生存的适度改善相关。
  • 专家组不推荐辅助地舒单抗用于预防乳腺癌复发,因研究未显示在任何早期乳腺癌亚组中一致降低复发。

核心结论

  • 辅助双膦酸盐治疗应与所有绝经后(自然或治疗所致)原发性乳腺癌且适合接受辅助全身治疗的患者讨论,不论激素受体和人表皮生长因子受体2状态。
  • 辅助双膦酸盐不能替代标准抗肿瘤治疗,其获益取决于基础复发风险,并与总生存的适度改善相关。
  • 专家组不推荐辅助地舒单抗用于预防乳腺癌复发,因研究未显示在任何早期乳腺癌亚组中一致降低复发。

研究设计与样本

  • ASCO-OH(CCO)专家小组通过系统检索识别新的、可能改变实践的数据,共4篇文章符合入选标准并构成修订既往推荐证据基础。

主要发现

  • 辅助双膦酸盐治疗的获益将因基础复发风险而异,并与总生存的适度改善相关。
  • NHS PREDICT工具可提供辅助双膦酸盐治疗获益的估计,并可能有助于决策。
  • 研究未显示辅助地舒单抗在任何早期乳腺癌亚组中一致降低乳腺癌复发。

关键数值与推荐

  • 当使用辅助双膦酸盐预防乳腺癌复发时,专家组推荐的治疗选择包括口服氯膦酸盐、口服伊班膦酸盐和静脉唑来膦酸。

临床怎么用

  • 影响推荐辅助双膦酸盐使用的因素应包括患者复发风险、副作用风险、经济毒性、药物可及性、患者偏好、合并症和预期寿命。
  • 专家组支持尽早开始双膦酸盐治疗,与母版CCO-ASCO指南所述要点一致;此为共识推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS: Four articles met eligibility criteria and form the evidentiary basis for revision of the previous recommendations. RECOMMENDATIONS: Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or therapy-induced) with primary breast cancer, irrespective of hormone receptor status and human epidermal growth factor receptor 2 status, who are candidates to receive adjuvant systemic therapy. Adjuvant bisphosphonates, if used, are not substitutes for standard anticancer modalities. The benefit of adjuvant bisphosphonate therapy will vary depending on the underlying risk of recurrence and is associated with a modest improvement in overall survival. The NHS PREDICT tool provides estimates of the benefit of adjuvant bisphosphonate therapy and may aid in decision making. Factors influencing the decision to recommend adjuvant bisphosphonate use should include patients' risk of recurrence, risk of side effects, financial toxicity, drug availability, patient preferences, comorbidities, and life expectancy. When an adjuvant bisphosphonate is used to prevent breast cancer recurrence, the therapeutic options recommended by the Panel include oral clodronate, oral ibandronate, and intravenous zoledronic acid. The Panel supports starting bisphosphonate therapy early, consistent with the points outlined in the parent CCO-ASCO guideline; this is a consensus recommendation. The Panel does not recommend adjuvant denosumab to prevent breast cancer recurrence, because studies did not show a consistent reduction of breast cancer recurrence in any subset of those with early-stage breast cancer.Additional information can be found at www.asco.org/breast-cancer-guideline.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eisen A, Somerfield MR, Accordino MK, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2022. PMID: 35041467. doi:10.1200/JCO.21.02647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。